Search

Your search keyword '"Neal, Joel W"' showing total 302 results

Search Constraints

Start Over You searched for: Author "Neal, Joel W" Remove constraint Author: "Neal, Joel W" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
302 results on '"Neal, Joel W"'

Search Results

1. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

2. Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors

3. Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

4. Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study

6. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

12. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

24. Racial and ethnic differences in second primary lung cancer risk among lung cancer survivors.

31. A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol

34. THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY

35. Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study

36. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non–Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison

37. Risk Model–Based Lung Cancer Screening and Racial and Ethnic Disparities in the US

38. Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer

39. Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.

40. Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked

41. Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials

42. Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials

43. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

44. Data from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials

45. Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model

46. The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG‐ACRIN Cancer Research Group trials

47. Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non–Small Cell Lung Cancer

49. Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

50. Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Catalog

Books, media, physical & digital resources